Menin inhibitors emerge as potential new treatment option for advanced acute leukemias healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.
A treatment called revumenib, which inhibits the protein menin, showed promising results for individuals with acute leukemia, and aided remission in 30% of study participants.
/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of.